Gilead Sciences Inc (GILD)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 480,000 | 126,000 | 1,053,000 | 484,000 | 5,664,000 | 5,875,000 | 5,484,000 | 5,583,000 | 4,585,000 | 3,327,000 | 4,130,000 | 4,508,000 | 6,225,000 | 7,394,000 | 5,162,000 | 301,000 | 123,000 | 1,268,000 | -257,000 | 4,962,000 |
| Total stockholders’ equity | US$ in thousands | 19,330,000 | 18,474,000 | 18,281,000 | 17,539,000 | 22,749,000 | 22,242,000 | 21,094,000 | 20,939,000 | 21,209,000 | 21,057,000 | 20,236,000 | 19,915,000 | 21,064,000 | 21,471,000 | 19,710,000 | 18,964,000 | 18,221,000 | 17,471,000 | 18,142,000 | 22,179,000 |
| ROE | 2.48% | 0.68% | 5.76% | 2.76% | 24.90% | 26.41% | 26.00% | 26.66% | 21.62% | 15.80% | 20.41% | 22.64% | 29.55% | 34.44% | 26.19% | 1.59% | 0.68% | 7.26% | -1.42% | 22.37% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $480,000K ÷ $19,330,000K
= 2.48%
The return on equity (ROE) of Gilead Sciences Inc has shown fluctuations over the analyzed periods. The ROE ranged from -1.42% to a high of 34.44%. Notably, there was a significant increase in ROE from June 2020 to December 2021, reaching its peak at 34.44% in September 2021. However, the ROE started to decline from March 2022 onwards, although it remained relatively healthy at levels above 20%.
The ROE measures the company's ability to generate profit from shareholder's equity. A higher ROE indicates that the company is more efficient in utilizing shareholders' funds to generate profits. Gilead Sciences Inc's ROE showed resilience during most periods, signifying efficient management of equity investments to generate earnings.
Despite occasional fluctuations, the company maintained a positive ROE throughout the analyzed period, which generally indicates that Gilead Sciences Inc has been effective in utilizing shareholder equity to drive profits. The company's ability to sustain ROE above 20% for a considerable part of the analysis period reflects a strong performance in generating returns for its shareholders. However, the decreasing trend in recent periods might warrant further investigation into potential factors affecting the company's profitability and efficiency in utilizing equity.
Peer comparison
Dec 31, 2024